Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis
Antidiabetic and lipid-lowering medication use was associated with lower serum liver fibrosis biomarkers. Among participants with European ancestry, associations between combined use of these medications and lower FIB-4 or APRI scores were stronger in those at high genetic risk of MASH. Longitudinal studies are warranted to extend upon these potentially clinically important findings.
Authors
- Andrew N. Billin (ORCID: https://orcid.org/0000-0001-7752-0934)
- Lisa Boyette
- Dora Ding
- Jason H. Melehani (ORCID: https://orcid.org/0000-0003-1794-6583)
- Shahed Iqbal (ORCID: https://orcid.org/0000-0002-3013-4750)
- Jun Xu (ORCID: https://orcid.org/0000-0002-4133-2533)
- Xiaorong Shao
- Jun Wang (ORCID: https://orcid.org/0000-0001-8372-1863)
- Lily Ma
- Vladislav A. Malkov
- Catherine Jia
- Timothy R. Watkins
Institutions
- Gilead Sciences (United States) (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1111/dom.16443
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Gilead Sciences